{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:46:25Z","timestamp":1787510785511,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.urology.2019.12.001","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:19:57Z","timestamp":1576610397000},"page":"50-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Onabotulinumtoxina Re-Injection for Refractory Detrusor Overactivity Using 3-4 Injection Sites: Results of a Pilot Study"],"prefix":"10.1016","volume":"137","author":[{"given":"Esther","family":"Mart\u00ednez-Cuenca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Bonillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Broseta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-9423","authenticated-orcid":false,"given":"Salvador","family":"Arlandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2019.12.001_bib0001","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol [Internet]"},{"key":"10.1016\/j.urology.2019.12.001_bib0002","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2019.12.001_bib0003","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.eururo.2012.01.046","article-title":"Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action","volume":"61","author":"Coelho","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2019.12.001_bib0004","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/nau.22780","article-title":"Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study","volume":"35","author":"Liao","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/nau.23052","article-title":"Less is more\u2014a pilot study evaluating one to three intradetrusor sites for injection of onabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity","volume":"36","author":"Avallone","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.12.001_bib0006","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1569-9056(07)60885-9","article-title":"BotulinumtoxinA","volume":"6","author":"Karsenty","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urology.2019.12.001_bib0007","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/nau.22954","article-title":"Efficay and safety of two administration modes","volume":"36","author":"Denys","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.12.001_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/toxins8030059","article-title":"Botulinum toxin a for the treatment of overactive bladder","volume":"8","author":"Hsieh","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.urology.2019.12.001_bib0009","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.urology.2019.12.001_bib0010","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.urology.2008.05.033","article-title":"Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder","volume":"72","author":"Colman","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.urology.2019.12.001_bib0011","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.medcli.2011.11.013","article-title":"Adaptaci\u00f3n cultural al Espa\u00f1ol y validaci\u00f3n psicom\u00e9trica de la Escala de Beneficio del Tratamiento (Treatment Benefit Scale -TBS) en el tratamiento sintom\u00e1tico de la vejiga hiperactiva","volume":"140","author":"Errando-Smet","year":"2013","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.urology.2019.12.001_bib0012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/nau.22530","article-title":"The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women","volume":"34","author":"Jimenez-Cidre","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.12.001_bib0013","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.juro.2016.04.046","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment","volume":"196","author":"Rovner","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2019.12.001_bib0014","first-page":"547","article-title":"Botulinum toxin A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-a prospective randomized study to compare 30 vs 10 injections sites","volume":"4-6","author":"Karsenty","year":"2005","journal-title":"Neururol Urodyn"},{"key":"10.1016\/j.urology.2019.12.001_bib0015","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2019.12.001_bib0016","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2019.12.001_bib0017","first-page":"S111","article-title":"Onabotulinumtoxina injections for idiopathic and neurogenic overactive bladder: discontinuation rates and reasons for treatment disruption in two Spanish hospitals","volume":"34","author":"Arlandis Guzman","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2019.12.001_bib0018","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519310970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519310970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:06:38Z","timestamp":1758765998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429519310970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":18,"alternative-id":["S0090429519310970"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2019.12.001","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onabotulinumtoxina Re-Injection for Refractory Detrusor Overactivity Using 3-4 Injection Sites: Results of a Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2019.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}